Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Braftovi“
Suchtreffer
Begriffe & Kennungen
Braftovi · 4.8 · 16 m includes, but not limited to, fluid retention, peripheral oedema, localised oedema, generalised oedema an
Eintrag öffnenBraftovi · 4.8 · 17 Ocular events Melanoma and NSCLC In the Combo 450 population, uveitis was reported in 3.5% (13/372) of pati
Eintrag öffnenBraftovi · 4.8 · 18 Pancreatitis Melanoma and NSCLC In the Combo 450 ISP, pancreatic enzyme elevation, mostly asymptomatic, was
Eintrag öffnenBraftovi · 4.8 · 19 Colorectal cancer Encorafenib and cetuximab combination In the population treated with encorafenib 300 mg i
Eintrag öffnenBraftovi · 4.8 · 20 CK elevation and rhabdomyolysis CK elevation and rhabdomyolysis occurred when encorafenib is used in combin
Eintrag öffnenBraftovi · 4.8 · 21 In Study CMEK162B2301-Part 2, in the Combo 300 arm, nausea was observed in 27.2% (70/257) of patients and w
Eintrag öffnenBraftovi · 4.8 · 22 Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in comb
Eintrag öffnenBraftovi · 4.8 · 23 Encorafenib with cetuximab and FOLFOX combination In the pooled EC+FOLFOX population (n=259), 166 patients
Eintrag öffnenBraftovi · 4.8 · Abdominal pain was reported in 36.6% (79/216) of patients and was Grade 3 in 5.1% (11/216) of patients. Nausea
Eintrag öffnenBraftovi · 4.8 · Adverse reactions are listed below by MedDRA body system organ class and the following frequency convention: v
Eintrag öffnenBraftovi · 4.8 · Anaemia Melanoma and NSCLC In the Combo 450 ISP, anaemia was reported in 23.1% (86/372) of patients; 7.0% (26/
Eintrag öffnenBraftovi · 4.8 · Basal cell Basal cell carcinoma* New Primary Uncommo Basal cell carcinoma* Melanoma* n carcinoma Blood and lym
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab and FOLFOX combination In the pooled EC+FOLFOX population, anaemia
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination Blood creatinine elevation was reported in 2.8% (6/216
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination Haemorrhagic events were observed in 21.3% (46/216) of
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in combina
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in combina
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in combina
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in combina
Eintrag öffnenBraftovi · 4.8 · Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in combina
Eintrag öffnen